BRKRP
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
NASDAQ · Healthcare · Medical - Devices · US
$433.55
−1.02%Year over year
Reported trailing growth
- Revenue
- +1.6%
- EBITDA
- -38.6%
- EBIT
- -31.2%
- EPS
- —
- Free cash flow
- +90.5%
- Operating cash flow
- +14.8%
Forward estimates
Based on analyst estimates
- Revenue
- +3.3%
- EBITDA
- +103.4%
- EPS
- +424.0%
Three-year CAGR
- Revenue
- +10.7%
- EBITDA
- -16.4%
- EBIT
- -18.3%
- Net income
- —
- EPS
- —
- Free cash flow
- -54.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026